PT  - JOURNAL ARTICLE
AU  - Marcin Pilarczyk
AU  - Michal Kouril
AU  - Behrouz Shamsaei
AU  - Juozas Vasiliauskas
AU  - Wen Niu
AU  - Naim Mahi
AU  - Lixia Zhang
AU  - Nicholas Clark
AU  - Yan Ren
AU  - Shana White
AU  - Rashid Karim
AU  - Huan Xu
AU  - Jacek Biesiada
AU  - Mark F. Bennett
AU  - Sarah Davidson
AU  - John F Reichard
AU  - Kurt Roberts
AU  - Vasileios Stathias
AU  - Amar Koleti
AU  - Dusica Vidovic
AU  - Daniel J.B. Clarke
AU  - Stephan C. Schurer
AU  - Avi Ma’ayan
AU  - Jarek Meller
AU  - Mario Medvedovic
TI  - Connecting omics signatures of diseases, drugs, and mechanisms of actions with iLINCS
AID  - 10.1101/826271
DP  - 2020 Jan 01
TA  - bioRxiv
PG  - 826271
4099  - http://biorxiv.org/content/early/2020/11/08/826271.short
4100  - http://biorxiv.org/content/early/2020/11/08/826271.full
AB  - There are only a few platforms that integrate multiple omics data types, bioinformatics tools, and interfaces for integrative analyses and visualization that do not require programming skills. Among these, iLINCS is unique in scope and versatility of the data provided and the analytics facilitated. iLINCS (http://ilincs.org) is an integrative web-based platform for analysis of omics data and signatures of cellular perturbations. The platform facilitates analysis of user-submitted omics signatures of diseases and cellular perturbations in the context of a large compendium of pre-computed signatures (>200,000), as well as mining and re-analysis of the large collection of omics datasets (>12,000), pre-computed signatures, and their connections. Analytics workflows driven by user-friendly interfaces enable users with only conceptual understanding of the analysis strategy to execute sophisticated analyses of omics signatures, such as systems biology analyses and interpretation of signatures, mechanism of action analysis, and signature-driven drug repositioning. In summary, iLINCS workflows integrate vast omics data resources and a range of analytics and interactive visualization tools into a comprehensive platform for analysis of omics signatures.Competing Interest StatementThe authors have declared no competing interest.